IceCure Medical (ICCM) Projected to Release Quarterly Earnings on Wednesday

IceCure Medical (NASDAQ:ICCM) will likely be posting its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect IceCure Medical to post earnings of ($1.5167) per share and revenue of $1.45 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 11:00 AM ET.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.03). The firm had revenue of $0.91 million for the quarter, compared to analyst estimates of $1.34 million. IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%. On average, analysts expect IceCure Medical to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

IceCure Medical Stock Performance

IceCure Medical stock opened at $3.13 on Wednesday. IceCure Medical has a fifty-two week low of $2.12 and a fifty-two week high of $42.00. The firm has a market capitalization of $10.74 million, a price-to-earnings ratio of -0.43 and a beta of 0.47. The stock’s fifty day moving average is $4.31 and its two-hundred day moving average is $10.65.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of IceCure Medical to a “sell” rating in a report on Sunday, July 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a report on Friday, July 17th. Maxim Group lowered their price target on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. Finally, Alliance Global Partners started coverage on shares of IceCure Medical in a research note on Monday, May 4th. They set a “buy” rating for the company. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $62.70.

Hedge Funds Weigh In On IceCure Medical

A hedge fund recently bought a new stake in IceCure Medical stock. Virtu Financial LLC bought a new position in shares of IceCure Medical Ltd. (NASDAQ:ICCM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 64,524 shares of the company’s stock, valued at approximately $39,000. Virtu Financial LLC owned about 0.09% of IceCure Medical as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.